Abstract
Progestogens appear to have a dual effect on the cell cycle in breast cells and breast cancer cells. There is initially stimulation of mitotic activity. However, continuous application leads to cell apoptosis. This depends on type, dose and length of progestogen application in relation to estrogen action. In benign breast disease the use of progestogens results not only in reduction of mastodynia, but also a reduction in breast gland size and disappearance of nodularity proven by clinical examination and follow-up including breast ultrasound.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schindler AE (1989) Ätiologie und Epidemiologie gutartiger Veränderungen der Brust. Gynäkologe 22:212–215
Eden J (2003) Progestins and breast cancer. Am J Obstet Gynecol 188:1123–1131
Sitruk-Ware R, Mishell DR (2000) Progestins and antiprogestins in clinical practice. Marcel Dekker, New York
Musgrove EA, Lee CSL, Sutherland R (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression, while increasing expression of transforming growth factor, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 11:5032–5043
Plu-Bureau G, Le M, Sitruk-Ware R, Thalabard J (1994) Progestogen use and the decreased risk of breast cancer in a cohort of premenopausal women with benign breast disease. Br J Cancer 70:270–277
Mauvais-Javis P (1988) Mastodynia and fibrocystic breast disease. Curr Ther Endocrinol Metab 3:280–284
Barrat J, de Lignieres B, Marpeau L et al (1990) Effect in vivo de l′adminstration locale de progesterone sur l′activité mitotique de galactophores humaines. J Gyn Obstet Biol Reprod 19:269–274
Chang KJ, Lee TTY, Linares-Gruz G (1995) Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fert Steril 63:785–791
Kutten F, Malet C, Leygue E et al (1994) Antiestrogen action of progestogens in human breast cells. In: Berg G, Hammar M (eds) The modern management of menopause. Canforth, Parthenon, pp 419–433
Rohan TE, Negassa A, Chlebowski RT et al (2008) Estrogen plus progestogen and risk of benign proliferative breast disease. Cancer Epidemiol Biomark Prev 17:2337–2343
Seeger H, Wallwiener D, Mueck AO (2003) The effect of progesterone and synthetic progestins in serum and estradiol-stimulated proliferation of human breast cancer cells. Hormone Metab Res 55:76
Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C (2001) Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol Endocrinol 15(Suppl 6):37–43
Goebel R, Junkermann R, von Fournier D (1989) Danazol-Therapie bei gutartigen Brusterkrankungen. Gynäkologe 22:262–270
Uzan S, Denis C, Pomi V, Varin C (1992) Double-blind trial of promegestone (R5020) and lynestrenol in the treatment of benign breast disease. Eur J Gynecol Obstet Reprod Biol 43:219–227
Vorher H (1988) Gutartige Brustveränderungen: Was ist in Praxi zu tun? Gyne International 6:5–10
Schindler AE, Henkel A, Christensen B, Moore C, Oettel M (2009) Dienogest and the breast. Gynecol Endocrinol 25:472–474
V Fournier D, Kubli F, Bauer M, Weber E (1981) Hochdosierte Gestagen-Langzeit-Therapie beim Corpuskarzinom, Einfluss auf Überlebenszeit. Geburtsh Frauenheilk. 41:266–270
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schindler, A.E. Dydrogesterone and other progestins in benign breast disease: an overview. Arch Gynecol Obstet 283, 369–371 (2011). https://doi.org/10.1007/s00404-010-1456-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-010-1456-7